• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by ASLAN Pharmaceuticals Limited (Amendment)

    7/13/23 4:57:22 PM ET
    $ASLN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ASLN alert in real time by email
    SC 13G/A 1 g711230sc13ga2.htm AMENDMENT NO. 2

     

     

    Securities and Exchange Commission

    Washington, DC 20549

     

    SCHEDULE 13G/A

     

     

    Under the Securities Exchange Act of 1934

    (Amendment No. 2)*

     

    ASLAN Pharmaceuticals Limited

    (Name of Issuer)

     

    Ordinary Shares as represented by American Depository Shares (“ADSs”),

    par value $0.01 per ordinary share**

    (Title of Class of Securities)

     

     

     

    04522R200***

    (CUSIP Number)

     

     

     

     

    July 11, 2023

    (Date of Event Which Requires Filing of This Statement)

     

     

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    o       Rule 13d-1(b)

     

    ý       Rule 13d-1(c)

     

    o       Rule 13d-1(d)

     

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    **Ordinary Shares are not for trading, but only in connection with the registration of the ADSs.

     

    ***CUSIP number assigned to the ADSs of the Company. Each ADS represents twenty-five Ordinary Shares.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     Page 1 of 8 
     

     

    CUSIP No. 04522R200

    13G/A Page 2 of 8 Pages
    1

    NameS of Reporting Persons
    I.R.S. Identification NOS. of Above Persons (ENTITIES ONLY)

     

    TANG CAPITAL PARTNERS, LP

     

    2 Check the Appropriate Box if a Member of a Group*                                            (a)    ¨
    (
    b)    ý
    3 SEC Use Only
     
    4

    Citizenship or Place of Organization

     

    DELAWARE

     

     

    Number of

    5

    Sole Voting Power

    0

     

    Shares

    BENEFICIALLY
    Owned by

    6

    Shared Voting Power

     

    45,155,180

    Each Reporting
    Person with
    7

    Sole Dispositive Power

     

    0

     

      8

    Shared Dispositive Power

     

    45,155,180

     

    9

    Aggregate Amount Beneficially Owned by each Reporting Person

     

    45,155,180

     

    10

    Check Box if the Aggregate Amount in Row (9) excludes certain shares

     

    ¨

    11

    Percent of Class represented by amount in row 9

     

    11.0%

     

    12

    type of reporting person

     

    pN

     

               

     Page 2 of 8 
     

     

    CUSIP No. 04522R200

    13G/A Page 3 of 8 Pages

    1

    NameS of Reporting Persons
    I.R.S. Identification NOS. of Above Persons (ENTITIES ONLY)

     

    Tang Capital Management, LLC

     

    2 Check the Appropriate Box if a Member of a Group*                                            (a)    ¨
    (
    b)    ý
    3 SEC Use Only
     
    4

    Citizenship or Place of Organization

     

    DELAWARE

     

     

    Number of

    5

    Sole Voting Power

    0

     

    Shares

    BENEFICIALLY
    Owned by

    6

    Shared Voting Power

     

    45,155,180

    Each Reporting
    Person with
    7

    Sole Dispositive Power

     

    0

     

      8

    Shared Dispositive Power

     

    45,155,180

     

    9

    Aggregate Amount Beneficially Owned by each Reporting Person

     

    45,155,180

     

    10

    Check Box if the Aggregate Amount in Row (9) excludes certain shares

     

    ¨

    11

    Percent of Class represented by amount in row 9

     

    11.0%

     

    12

    type of reporting person

     

    OO

     

               

     Page 3 of 8 
     

     

    CUSIP No. 04522R200

    13G/A Page 4 of 8 Pages

    1

    NameS of Reporting Persons
    I.R.S. Identification NOS. of Above Persons (ENTITIES ONLY)

     

    Kevin Tang

     

    2 Check the Appropriate Box if a Member of a Group*                                            (a)    ¨
    (
    b)    ý
    3 SEC Use Only
     
    4

    Citizenship or Place of Organization

     

    united states

     

     

    Number of

    5

    Sole Voting Power

    0

     

    Shares

    BENEFICIALLY
    Owned by

    6

    Shared Voting Power

     

    45,155,180

    Each Reporting
    Person with
    7

    Sole Dispositive Power

     

    0

     

      8

    Shared Dispositive Power

     

    45,155,180

     

    9

    Aggregate Amount Beneficially Owned by each Reporting Person

     

    45,155,180

     

    10

    Check Box if the Aggregate Amount in Row (9) excludes certain shares

     

    ¨

    11

    Percent of Class represented by amount in row 9

     

    11.0%

     

    12

    type of reporting person

     

    IN

     

               

     Page 4 of 8 
     

     

    Item 1(a).Name of Issuer:

     

    ASLAN Pharmaceuticals Limited, a Delaware corporation (the “Issuer”)

     

    Item 1(b).Address of Issuer’s Principal Executive Offices:

     

    3 Temasek Avenue, Level 18 Centennial Tower, Singapore 039190

     

    Item 2(a).Name of Person Filing:

     

    This Statement on Schedule 13G (this “Statement”) is filed by Tang Capital Partners, LP (“Tang Capital Partners”); Tang Capital Management, LLC, the general partner of Tang Capital Partners (“Tang Capital Management”); and Kevin Tang, the manager of Tang Capital Management.

     

    Item 2(b).Address of Principal Business Office or, if none, Residence:

     

    4747 Executive Drive, Suite 210, San Diego, CA 92121

     

    Item 2(c).Citizenship:

     

    Tang Capital Partners is a Delaware limited partnership. Tang Capital Management is a Delaware limited liability company. Mr. Tang is a United States citizen.

     

    Item 2(d).Title of Class of Securities:

     

    Ordinary Shares, par value $0.01 per share, represented by ADSs (the “Ordinary Shares”)

     

    Item 2(e). CUSIP number 04522R200 has been assigned to the ADSs of the Company. Each ADS represents twenty-five Ordinary Shares.

     

    Item 3.Not applicable.

     

    Item 4.Ownership.

     

    (a)Amount Beneficially Owned:

     

    Tang Capital Partners. Tang Capital Partners beneficially owns 45,155,180 Ordinary Shares of the Issuer, which consists of (1) 1,806,207 ADSs and (2) 5 Ordinary Shares.

     

    Tang Capital Partners shares voting and dispositive power over such shares with Tang Capital Management and Kevin Tang.

     

    Tang Capital Management. Tang Capital Management beneficially owns 45,155,180 Ordinary Shares of the Issuer, which consists of (1) 1,806,207 ADSs and (2) 5 Ordinary Shares.

     

    Tang Capital Management shares voting and dispositive power over such shares with Tang Capital Partners and Kevin Tang.

     

    Kevin Tang. Kevin Tang beneficially owns 45,155,180 Ordinary Shares of the Issuer, which consists of (1) 1,806,207 ADSs and (2) 5 Ordinary Shares.

     

     Page 5 of 8 
     

     

    Kevin Tang shares voting and dispositive power over such shares with Tang Capital Partners and Tang Capital Management.

     

    The percentages used herein are based on 408,681,230 Ordinary Shares outstanding as of February 28, 2023, as set forth in the Issuer’s Registration Statement filed on Form F-3 that was filed with the Securities and Exchange Commission on March 24, 2023.

     

    (b)Percent of Class:

     

    Tang Capital Partners 11.0%
    Tang Capital Management 11.0%
    Kevin Tang 11.0%

     

    (c)Number of shares as to which such person has:

     

    (i)sole power to vote or to direct the vote:

     

    Tang Capital Partners 0 shares
    Tang Capital Management 0 shares
    Kevin Tang 0 shares

     

    (ii)shared power to vote or to direct the vote:

     

    Tang Capital Partners 45,155,180 shares
    Tang Capital Management 45,155,180 shares
    Kevin Tang 45,155,180 shares

     

    (iii)sole power to dispose or to direct the disposition of:

     

    Tang Capital Partners 0 shares
    Tang Capital Management 0 shares
    Kevin Tang 0 shares

     

    (iv)shared power to dispose or to direct the disposition of:

     

    Tang Capital Partners 45,155,180 shares
    Tang Capital Management 45,155,180 shares
    Kevin Tang 45,155,180 shares

     

    Item 5.Ownership of Five Percent or Less of a Class.

     

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following: ¨

     

    Item 6.Ownership of More than Five Percent on Behalf of Another Person.

     

    Not applicable

     

    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company.

     

    Not applicable.

     

    Item 8.Identification and Classification of Members of the Group.

     

    Not applicable.

     

     Page 6 of 8 
     

     

    Item 9.Notice of Dissolution of Group.

     

    Not applicable.

     

    Item 10.Certification.

     

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

     

     Page 7 of 8 
     

     

    Signature

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Date: July 13, 2023  
       
       
    TANG CAPITAL PARTNERS, LP
       
    By: Tang Capital Management, LLC, its General Partner
       
       
    By: /s/ Kevin Tang  
      Kevin Tang, Manager
       
       
    TANG CAPITAL MANAGEMENT, LLC
       
       
    By: /s/ Kevin Tang  
      Kevin Tang, Manager
       
       
    /s/ Kevin Tang  
    Kevin Tang

     

     

    Page 8 of 8

     

     

     

    Get the next $ASLN alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ASLN

    DatePrice TargetRatingAnalyst
    7/9/2021$8.00Buy
    Jefferies
    More analyst ratings

    $ASLN
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • ASLAN Pharmaceuticals Announces it Has Filed for Voluntary Liquidation of Its Sole Operating Subsidiary and is Commencing Steps to Place Itself Into Voluntary Liquidation

      Following a thorough review of all strategic alternatives, ASLAN Pharmaceuticals Pte Ltd, the sole operating subsidiary of ASLAN Pharmaceuticals, has filed for voluntary liquidation Quantuma (Singapore) Pte Limited International has been appointed as the official liquidator and will seek potential strategic alternatives for the Company's development programs, eblasakimab and farudodstat SAN MATEO, Calif. and SINGAPORE, July 17, 2024 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals ("ASLAN" or the "Company"), a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced that its Singapore-incorporated, sole oper

      7/17/24 7:25:04 AM ET
      $ASLN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • ASLAN Pharmaceuticals Announces Receipt of Nasdaq Delisting Determination; Has Determined Not to Appeal

      SAN MATEO, Calif. and SINGAPORE, July 15, 2024 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (("ASLAN" or the "Company", NASDAQ:ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced that on July 9, 2024, the Company was notified by the staff of the Listing Qualifications Department (the "Staff") of The Nasdaq Stock Market LLC ("Nasdaq") that, based upon the Company's non-compliance with the $1.00 bid price and $2.5 million stockholders' equity requirements for continued listing on The Nasdaq Capital Market, as set forth in Nasdaq Listing Rules 5550(a)(2) and 5550(b)(1), respectively, the Staff

      7/15/24 7:30:00 AM ET
      $ASLN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • ASLAN Pharmaceuticals Announces Plan to Implement ADS Ratio Change

      SAN MATEO, Calif. and SINGAPORE, June 14, 2024 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (("ASLAN" or the "Company", NASDAQ:ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced that it plans to change the ratio of the American Depositary Shares ("ADSs") to its ordinary shares, par value $0.01 per share, from one (1) ADS representing twenty-five (25) ordinary shares to one (1) ADS representing two hundred (200) ordinary shares. For the Company's existing ADS holders, the change in the ADS ratio will have the same effect as a one-for-eight reverse ADS split. There will be no change to the C

      6/14/24 4:54:19 PM ET
      $ASLN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ASLN
    SEC Filings

    See more
    • SEC Form 25-NSE filed by ASLAN Pharmaceuticals Limited

      25-NSE - ASLAN Pharmaceuticals Ltd (0001722926) (Subject)

      9/6/24 7:41:52 AM ET
      $ASLN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by ASLAN Pharmaceuticals Limited

      SCHEDULE 13G/A - ASLAN Pharmaceuticals Ltd (0001722926) (Subject)

      8/8/24 11:36:38 AM ET
      $ASLN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 6-K filed by ASLAN Pharmaceuticals Limited

      6-K - ASLAN Pharmaceuticals Ltd (0001722926) (Filer)

      7/17/24 7:29:55 AM ET
      $ASLN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ASLN
    Leadership Updates

    Live Leadership Updates

    See more
    • ASLAN Pharmaceuticals Announces New Translational Data on Eblasakimab in COPD and Appoints Leading Respiratory Experts as Scientific Advisors

      New translational data from a head-to-head study of eblasakimab and dupilumab in a human tissue model of COPD shows eblasakimab performed better than dupilumab in improving airway function and enhancing bronchodilation at the same concentrationsLeading respiratory experts, Ramaswamy Krishnan, PhD, and Reynold Panettieri, MD, appointed as scientific advisors to provide strategic counsel on eblasakimab's differentiation for future clinical development in COPD SAN MATEO, Calif. and SINGAPORE, March 06, 2024 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals Ltd. (NASDAQ:ASLN), a clinical-stage, immunology focused biopharmaceutical company developing innovative treatments to transform the lives of p

      3/6/24 7:00:00 AM ET
      $ASLN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • ASLAN Pharmaceuticals Appoints Dermatology Veteran Dr Alex Kaoukhov as Chief Medical Officer

      - Dermatologist with over twenty years of experience in senior biopharma roles in the US and Europe, including positions at Almirall, Allergan and Novartis- Strengthens leadership team as eblasakimab (also known as ASLAN004) moves into late-stage trials MENLO PARK, Calif. and SINGAPORE, March 15, 2022 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (NASDAQ:ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced the appointment of Alex Kaoukhov, MD, as Chief Medical Officer based in ASLAN's US office, effective immediately. Alex was most recently Head of Clinical Development, Senior Vice President

      3/15/22 7:00:00 AM ET
      $ASLN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • ASLAN Pharmaceuticals and IQVIA Biotech Enter Into Strategic Collaboration

      MENLO PARK, Calif. and SINGAPORE, Dec. 06, 2021 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (NASDAQ:ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced the appointment of IQVIA Biotech, a leading global provider of advanced analytics, technology solutions, and clinical research services to the life sciences industry, as its preferred clinical research organization for logistics related to decentralized clinical trials, including the global oversight, expansion and engagement of patients for trials related to the clinical development of ASLAN004 and ASLAN003. IQVIA Biotech will provide pati

      12/6/21 7:00:00 AM ET
      $ASLN
      $IQV
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Commercial Physical & Biological Resarch

    $ASLN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Jefferies initiated coverage on ASLAN Pharmaceuticals with a new price target

      Jefferies initiated coverage of ASLAN Pharmaceuticals with a rating of Buy and set a new price target of $8.00

      7/9/21 7:45:23 AM ET
      $ASLN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • HC Wainwright & Co. reiterated coverage on ASLAN Pharmaceuticals with a new price target

      HC Wainwright & Co. reiterated coverage of ASLAN Pharmaceuticals with a rating of Buy and set a new price target of $8.00 from $5.00 previously

      3/17/21 6:40:11 AM ET
      $ASLN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ASLN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by ASLAN Pharmaceuticals Limited

      SC 13G - ASLAN Pharmaceuticals Ltd (0001722926) (Subject)

      3/21/24 4:42:13 PM ET
      $ASLN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by ASLAN Pharmaceuticals Limited

      SC 13G - ASLAN Pharmaceuticals Ltd (0001722926) (Subject)

      3/19/24 4:30:30 PM ET
      $ASLN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by ASLAN Pharmaceuticals Limited (Amendment)

      SC 13G/A - ASLAN Pharmaceuticals Ltd (0001722926) (Subject)

      2/14/24 4:45:26 PM ET
      $ASLN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ASLN
    Financials

    Live finance-specific insights

    See more
    • ASLAN Pharmaceuticals Announces Positive Data Conclusively Establishing Proof of Concept for ASLAN004 in Atopic Dermatitis

      - Topline data from multiple-ascending-dose study supports a potentially differentiated safety and efficacy profile - ASLAN004 achieved a statistically significant improvement (p<0.0251) versus placebo in the primary efficacy endpoint of percent change from baseline in EASI with significant improvements in other efficacy endpoints- Well-tolerated with no cases of conjunctivitis in the expansion cohort- On track to enroll first patient in global Phase 2b study in 4Q 21- Management to host conference call and webcast today, 27 September, at 8am ET / 8pm SGTMENLO PARK, Calif. and SINGAPORE, Sept. 27, 2021 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (NASDAQ:ASLN), a clinical-stage, immunology

      9/27/21 6:00:00 AM ET
      $ASLN
      Biotechnology: Pharmaceutical Preparations
      Health Care